105 related articles for article (PubMed ID: 10695025)
21. [Survey of sensitivities of clinical isolates to antibacterial agents (annual report)].
Igari J; Inoue M; Nishino T; Watanabe N; Uehara N; Yoshida H; Imafuku Y; Shibano T; Satou S; Kobayashi I; Takahashi A; Yomoda S; Oguri T; Kumasaka K; Okada J; Hirata Y; Uchida K; Kawaguchi R; Ohtaki Y; Ishigo S; Okamoto E; Murakami E; Matsuoka K; Tokuda K; Saeki H
Jpn J Antibiot; 1997 Aug; 50(8):683-703. PubMed ID: 9339395
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
23. [In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
Fukuoka T; Inoue H; Abe T; Ohya S
Jpn J Antibiot; 2001 Jul; 54(7):365-71. PubMed ID: 11560055
[TBL] [Abstract][Full Text] [Related]
24. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
25. [The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Fujiue Y; Kuwabara M; Muroki K; Shimizu S; Watanabe Y; Awaya Y; Kodomari Y
Jpn J Antibiot; 1998 Jan; 51(1):26-36. PubMed ID: 9557274
[TBL] [Abstract][Full Text] [Related]
26. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M
Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404
[TBL] [Abstract][Full Text] [Related]
27. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].
Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Shinagawa M; Yasujima M; Suwabe A; Kuroda M; Kaku M; Kitagawa M; Kanemitsu K; Imafuku Y; Murakami M; Yomodu S; Taniguchi N; Yamada T; Nomura F; Kanno H; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Horikawa Y; Maekawa M; Nagura O; Yagi T; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kawano S; Kinoshita S; Taminato T; Negayama K; Murase M; Miyamoto H; Kusano N; Nose M; Yokozaki M; Itaha H; Matsunaga A; Yoshimura H; Kohno S; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
Jpn J Antibiot; 2011 Apr; 64(2):53-95. PubMed ID: 21721247
[TBL] [Abstract][Full Text] [Related]
28. Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistant Enterobacteriaceae.
Piddock LJ; Turner HL
Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1186-91. PubMed ID: 1291320
[TBL] [Abstract][Full Text] [Related]
29. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Tasaka K; Ishida A; Chinzei T
Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
[TBL] [Abstract][Full Text] [Related]
30. [In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA].
Sato S; Miura T; Kudo E; Kudo Y; Saitoh Y; Kimpara I; Tsujino M; Kudo H
Jpn J Antibiot; 1997 Aug; 50(8):711-6. PubMed ID: 9339397
[TBL] [Abstract][Full Text] [Related]
31. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Watanabe Y; Fujiue Y; Yano S; Shimizu S; Muroki K; Doi M; Kuwabara M
Jpn J Antibiot; 2006 Apr; 59(2):65-71. PubMed ID: 16805317
[TBL] [Abstract][Full Text] [Related]
32. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
33. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
[TBL] [Abstract][Full Text] [Related]
34. [In vitro antibacterial activities of carbapenems against clinical isolates].
Murase M
Jpn J Antibiot; 1999 Nov; 52(11):667-79. PubMed ID: 10659443
[TBL] [Abstract][Full Text] [Related]
35. [Antimicrobial activities of cefepime against clinically isolated strains].
Suzuki Y; Koguchi M; Tanaka S; Fukayama S; Ishihara R; Deguchi K; Oda S; Nakane Y; Fukumoto T
Jpn J Antibiot; 1995 Dec; 48(12):1906-19. PubMed ID: 8587165
[TBL] [Abstract][Full Text] [Related]
36. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
38. [Survey of the sensitivities of clinical isolates to antibacterial agents (annual report)].
Igari J; Shibano T; Satou S; Inoue M; Kobayashi I; Takahashi A; Yomoda S; Nishino T; Oguri T; Watanabe N; Uehara N; Kumasaka K; Yoshida H; Imafuku Y; Kobayasi Y; Okada J; Tokuda K; Hirata Y; Nakasaki N; Hongo T; Kawaguchi R; Ohtaki Y; Sasaki T; Matsumoto N; Saeki H
Jpn J Antibiot; 1999 Apr; 52(4):279-91. PubMed ID: 10396685
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
40. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2012].
Yamaguchi K; Ishii Y; Tateda K; Iwata M; Watanabe N; Shinagawa M; Kayaba H; Kimura M; Suwabe A; Kaku M; Abe Y; Kanemitsu K; Taniguchi N; Murakami M; Maesaki S; Kawamura T; Nomura F; Watanabe M; Kanno H; Horiuchi H; Tazawa Y; Kondo S; Misawa S; Takemura H; Nakashima H; Matsuto T; Fujimoto Y; Ishigo S; Gotoh H; Watanabe O; Yagi T; Shimaoka N; Mikamo H; Yamagishi Y; Fujita N; Komori T; Ichiyama S; Kawano S; Nakayama A; Nakamura F; Kohno H; Fukuda S; Kusano N; Nose M; Yokozaki M; Onodera M; Murao K; Negayama K; Nishimiya T; Miyamoto H; Matsunaga A; Yoshimura H; Kohno S; Yanagihara K; Hiramatsu K
Jpn J Antibiot; 2014 Apr; 67(2):73-107. PubMed ID: 24956909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
